Tissue Engineering & Stem Cell Technology Report 2007

Tissue Engineering & Stem Cell Technology Report 2007

Over 160+ pages dedicated to tissue engineering and stem cell analysis.

The market potential of this technology is so huge that revenues may be in excess of $10 billion by 2013. This is a market that you should be part of - NOW!! With a complex regulatory structure still to overcome, yet continued high level investment, many of your competitors are aware of the the commercial opportunities within Tissue Engineering & Stem Cell Technology.

Tissue engineering, the manufacture of complete tissues outside of the body ready for future transplant use, is already with us, including several types of replacement skin and a cartilage substitute. The estimated market for future tissue engineered products including the regeneration of bone, cartilage, and other connective structural treatments is worth approximately $5 billion worldwide.

The report ‘Tissue Engineering and Stem Cell Technology Report 2007’ will analyse these two highly lucrative markets for you and will include:

1. An in-depth explanation of the physiology behind stem cell technology
2. A listing of over 100 companies involved and a survey of the principle companies in stem cell development
3. An examination of the products in development & the likely clinical areas for future treatments
4. An in-depth assessment of the future markets delivered to you today
5. A thorough examination of the ethical and regulatory aspects behind stem cell research
6. A detailed analysis of the financial position of the market as it stands and future projections of growth

Methodology

The information contained in this report is from primary industry sources. This includes one-on-one interviews with companies, with governmental bodies and academic insitutions. Analysis has also been drawn from company reports, whether annual financial returns or white papers. The author of this report has dealt with over 50+ companies and industry contacts to assist on the production of this report.

Targeted directly at you this report is designed to be used primarily by executives, investors, venture capitalists, and business development managers and analysts involved in the pharmaceutical or biotechnology areas that may have an interest in stem cell technology.

This market has grown rapidly since the isolation of embryonic stem cells in 1998. With the technologies that impact stem cells catching up to the rate of research, now is your last chance to corner a section of this market.

It is the multifaceted role of stem cells in a whole wide range of diseases that accounts for this huge potential. The diseases that stem cell technology may offer treatments for includes:

1. Parkinson’s Disease
2. Diabetes
3. Chronic Heart Disease
4. Kidney Disease
5. Liver Failure
6. Cancer
7. Spinal Cord Injury
8. Multiple Sclerosis
9. Alzheimer’s Disease
10. Gene Therapy

Why you must buy this report:

The pharmaceutical industry has been seeking the next blockbuster drug, yet it appears as though these might not be as profligate as they have been in the past. However, the tissue engineering & stem cell treatment hold promise. This report analyses the current situation in the market and assesses the potential of work that are currently in the pipeline. You and your company should be part of this market, and you could be by placing your order immediately.

Unique benefits to you when you order this report

- Immediate access through our exclusive Reading Room
- You can access your report whichever country you are in without using harddrive space
- Primary research throughout. You will not find this information anywhere else
- Report stored in your reading room for ever
- Full searchable report when you buy the company or corporate editions
- Copies can be printed off for offline reading
- Packed with charts, analysis, figures, graphs and tables

If you buy one report this year make sure it is the report that will guarantee your success for the forthcoming years. Order this report now.

Chapter 1. Introduction
1.1 Introduction
1.2 Stem cells
1.2.1 History
1.2.2 Definitions
1.3 Embryonic stem (ES) cells
1.4 Embryonic germ (EG) cells
1.4.1 Embryonic stem (ES) cells versus embryonic germ (EG) cells
1.5 Adult stem cells
1.5.1 Advantages of adult stem cells
1.5.2 Disadvantages of adult stem cells
1.5.3 Adult stem cell plasticity and transdifferentiation
1.5.4 Questions about adult stem cells
1.6 Cloning
1.6.1 Therapeutic cloning
1.6.2 Reproductive cloning
1.6.3 Dolly the sheep
1.6.4 Other cloning successes
1.7 Tissue engineering
1.7.1 History
1.7.2 Progress
1.8 Conclusions

Chapter 2. Key players
2.1 Introduction
2.1.1 Novocell
2.1.2 ES Cell International
2.1.3 Reliance Life Sciences
2.1.4 Cytori Therapeutics
2.1.5 Intercytex
2.2 Companies that have stem cell lines currently stored at the NIH Human Embryonic Stem Cell Registry in the US
2.2.1 BresaGen
2.2.2 Cellartis
2.2.3 Cythera/ Novocell
2.2.4 ES Cell International (ESI)
2.2.5 Geron
2.2.6 Reliance Life Sciences
2.3 Pharmaceutical industry
2.3.1 Amersham
2.3.2 Amgen
2.3.3 AstraZeneca
2.3.4 Johnson & Johnson
2.3.5 Merck
2.3.6 Novartis AG
2.3.7 Schering AG
2.4 Key companies - US
2.4.1 Aarstrom Biosciences Inc.
2.4.2 Advanced Cell Technology Inc.
2.4.3 BioE
2.4.4 Cellerant
2.4.5 Cytori Therapeutics
2.4.6 Genentech
2.4.7 Osiris
2.4.8 Stem Cells Inc.
2.4.9 Stem Cell Therapeutics Corp
2.4.10 Titan Pharmaceuticals Inc.
2.4.11 Viacell
2.5 Key companies - UK
2.5.1 Angel BioTechnology
2.5.2 Axordia
2.5.3 Epistem
2.5.4 Intercytex
2.5.5 Novathera
2.5.6 Odontis
2.5.7 RegenTec
2.5.8 Reinnervate
2.5.9 ReNeuron
2.5.10 Renovo
2.5.11 Stem Cell Sciences
2.6 Key companies - global
2.6.1 Australia
2.6.1.1 Mesoblast Limited
2.6.2 Israel
2.6.2.1 Pluristem
2.6.2.2 BrainStorm Cell Therapeutics
2.6.2.3 Gamida
2.6.3 Thailand
2.6.3.1 TheraVitae
2.6.4 India
2.6.4.1 Stempeutics
2.6.5 Singapore
2.6.6 Sweden
2.7 Other companies
2.7.1 Bioheart, Inc.
2.7.2 Aldagen
2.7.3 Cellular Dynamics International
2.7.4 RhinoCyte
2.7.5 Stem Cell Innovations
2.7.6 StemCell Technologies
2.7.7 Vesta Therapeutics
2.7.8 Vistagen Therapeutics
2.8 Conclusions

Chapter 3. The Market
3.1 Introduction
3.2 The Global burden of disease
3.3 Numbers of patients
3.4 Cost of illness
3.5 Major clinical applications
3.5.1 Cardiac applications
3.5.2 Other circulatory applications
3.5.3 Cosmetic applications
3.5.4 Dermatological applications
3.5.5 Endocrine applications
3.5.6 Hepatic applications
3.5.7 Neural applications
3.5.8 Optical applications
3.5.9 Orthodontic applications
3.5.10 Orthopaedic applications
3.5.11 Renal applications
3.5.12 Other applications
3.6 Regenerative medicine market
3.6.1 Stem cell market
3.6.2 Media coverage
3.6.3 Tissue engineering
3.7 Conclusions

Chapter 4. Issues
4.1 Introduction
4.2 Ethical Issues
4.2.1 The Ethics of how life is defined
4.2.2 The Ethics of using stem cells
4.3 Social Issues
4.3.1 Tissue source
4.3.2 Hybrids
4.3.3 Long term implications of stem cell research
4.4 Moral issues
4.5 Religious issues
4.5.1 Catholicism
4.5.2 Protestantism
4.5.3 Judaism
4.5.4 Islam
4.5.5 Hinduism
4.6 Political issues
4.6.1 US
4.7 Conclusions

Chapter 5. Regulations and patents
5.1 Introduction
5.2 Regulatory issues
5.2.1 UK Government initiatives
5.2.2 UK Stem cell bank
5.2.3 UK - Current regulations
5.2.4 US Government initiatives
5.2.4.1 History
5.2.4.2 Appropriations Bill, HR 3061 (Sec. 510)
5.2.5 US Current regulations
5.2.6 Ongoing controversy
5.2.7 Political landscape
5.2.8 Cell line viability
5.2.9 Xenotransplantation
5.2.10 Rest of World
5.2.11 Europe
5.2.12 Asia
5.2.12.1 Japan
5.2.12.2 China
5.2.12.3 Singapore
5.2.12.4 India
5.2.12.5 South Korea
5.2.13 Australia
5.2.14.1 Canada
5.2.14.2 South America
5.2.13 Australasia
5.2.14 Canada and South America
5.2.15 Middle East
5.2.16 Africa
5.3 Conclusions
5.4 Patenting Issues
5.4.1 Background
5.4.2 Patenting - Europe
5.4.3 Patenting - UK
5.4.3.1 Processes for obtaining stem cells from human embryos
5.4.3.2 Human totipotent cells
5.4.3.3 Human embryonic pluripotent cells
5.4.4 Patenting - USA
5.4.4.1 Wisconsin Alumni Research Foundation (WARF)
5.4.4.2. Geron
5.4.5 Patenting controversy
5.4.6 Patenting - global
5.5 Conclusions

Chapter 6. Trends, Drivers and Opportunities
6.1 Introduction
6.2 Stem Cell Research - SWOT analysis
6.2.1 Strengths
6.2.2 Weaknesses
6.2.3 Opportunities
6.2.4 Threats
6.3 Trends
6.3.1 Portfolio diversification
6.3.2 Strong proprietary rights
6.3.3 Strategic partnerships
6.4 Drivers
6.4.1 Funding
6.4.2 Results
6.5 Opportunities
6.5.1 Suppliers to the stem cell industry
6.5.2 Cord blood banking
6.6 Conclusions

Chapter 7. Stem cell research funding
7.1 Introduction
7.2 Charities and research councils
7.2.1 Wellcome Trust/ Juvenile Diabetes Research Foundation
7.2.2 Wellcome Trust/ Medical Research Council/ Wolfson Foundation
7.2.3 Juvenile Diabetes Research Foundation (JDRF)
7.3 Private funds
7.3.1 The Starr Foundation
7.3.2 Ansary Center for Stem Cell Therapeutics
7.3.3 Johns Hopkins.
7.3.4 University of Texas Health Centre
7.3.5 University of California, San Francisco (UCSF)
7.4 Public funds
7.4.1 Venture Capital
7.4.2 Other public funds
7.4.3 California
7.4.4 New Jersey
7.4.5 Massachusetts
7.4.6 Connecticut
7.4.7 Illinois
7.4.8 Maryland
7.4.9 Ohio
7.4.10 Others
7.4.11 European Union
7.5 Conclusions

Chapter 8. Conclusions - the future of the stem cell market
8.1 Introduction
8.2 Progress
8.2.1 Science
8.2.2 Media
8.2.3 Geography
8.2.4 Funding
8.2.5 Patenting
8.2.6 Politics
8.3 Recommendations

List of tables
Table 1.1 Key achievements in stem cell research
Table 1.2 Diseases and conditions treated with adult stem cell therapies
Table 2.1 Organisations currently listed as the supplier of stem cell lines to the NIH Human Embryonic Stem Cell Registry
Table 3.1 The world top 20 threats to health in 2002 and projected 2030
Table 3.2 Number of potential patients in the US eligible for stem cell therapy
Table 3.3 Annual direct expenditure in the US for leading diseases and conditions
Table 3.4 Top surgical and non-surgical cosmetic procedures for men and women (2005)
Table 5.1 Representative state-wide initiatives regarding the application of stem cell research
Table 5.2 EU member states legislation (2006)

List of figures
Figure 1.1 Number of papers published per annum (1996-2006)
Figure 1.2 Schematic of embryonic stem cell differentiation
Figure 1.3 Lung cells derived from human embryonic stem cells
Figure 1.4 Foetal neural stem cells
Figure 1.5 Schematic of embryonic tissue differentiation
Figure 5.1 Published patents (1997 - 2005), Title search: ``Stem cell*``, ``Embryonic stem cell*`` and ``Human embryonic stem cell*``
Figure 5.2 Number of key patent families (2000 - 2005)
Figure 7.1 Current translation pathway for stem cell research to commercialisation